Table of Contents
- 1 For Immediate Release
- 2 Here are highlights from Tuesday’s Analyst Blog:
- 3 4 Stocks to Watch on Rising Demand for Scientific Instruments
- 4 Industry Description
- 5 3 Trends Shaping the Future of Instruments-Scientific Industry
- 6 Zacks Industry Rank Indicates Solid Prospects
- 7 Industry Lags Sector and S&P 500
- 8 Industry’s Current Valuation
- 9 4 Scientific Instruments Providers to Watch
For Immediate Release
Chicago, IL – September 9, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Mettler-Toledo International MTD, PerkinElmer PKI, Waters Corporation WAT and Bruker Corporation BRKR.
Here are highlights from Tuesday’s Analyst Blog:
4 Stocks to Watch on Rising Demand for Scientific Instruments
The coronavirus pandemic has created unique opportunities for the Zacks Instruments – Scientific industry participants — Mettler-Toledo International, PerkinElmer, Waters Corporation and Bruker Corporation.
These companies are gaining from solid demand for coronavirus testing tools as well as rising instrument orders across the globe. Moreover, increasing spending on health care driven by an aging demography and continued innovation in the pharma and life sciences end-markets are key catalysts despite coronavirus-induced macroeconomic uncertainties.
Further, the anticipated reopening of university research laboratories as well as applied and industrial labs globally is a driving factor for the near term.
The Zacks Instruments – Scientific industry comprises companies offering scientific instruments, analytical tools, diagnostic solutions, precision instruments & services, and test & sensor solutions.
The primary end-markets served by the industry participants are life science research in academia, medical schools and government, pharmaceuticals and biotechnology, microbiology and diagnostics, nanotechnology, and materials science research. A few companies also serve the food and nutritional safety, biochemical, and industrial spaces.
Most of the industry participants are under stringent regulatory scrutiny worldwide. They have to adhere to the U.S. Food and Drug Administration (FDA) norms as well as rules set by other global regulatory bodies for serving highly regulated end-markets like life sciences and pharma.
3 Trends Shaping the Future of Instruments-Scientific Industry
Strong End-Market Demand:The industry is benefiting from strong end-market demand, particularly from the life science, pharmaceutical and academic markets. Increasing demand for generic drugs and biosimilars is driving growth for scientific tool and apparatus providers. Additionally, pharma companies are focusing on rapidly growing areas like proteomics and phenomics, biopharma and applied, microbiology and diagnostics, and neuroscience and cell microscopy, which creates significant demand for the instruments provided by industry participants.
Aging Demography Driving Spending:Socioeconomic factors like an aging demography and increasing environmental regulations are driving demand for scientific measurement solutions. Moreover, robust worldwide healthcare spending is a major growth driver. Notably, the U.S. House of Representatives has voted to increase the National Institute of Health’s (NIH) fiscal 2021 budget by $5.275 billion, including a $470-million boost to the National Cancer Institute. NIH’s proposed budget is $8.26 billion more than President Donald Trump’s proposal of a $2.3-billion cut. Markedly, NIH has already received $3.6 billion for COVID-19 research in a series of emergency stimulus bills.
Solid Emerging Market Prospects: Further, the industry is gaining from increasing exposure to developing economies like China and India. Prospects in China are huge as regulators are attempting to raise the country’s biopharma industry to global standards. Moreover, efforts to improve the drug development process and production quality in the country are noteworthy. These factors are resulting in strong demand for instruments. However, any undesirable turn in the recent trade spat between the United States and China will not augur well for some of the industry players.
Zacks Industry Rank Indicates Solid Prospects
The Zacks Instruments – Scientific industry is housed within the broader Zacks Computer and Technology sector. It carries a Zacks Industry Rank #80, which places it at the top 32% of more than 250 Zacks industries.
The group’s Zacks Industry Rank, which is basically the average of the Zacks Rank of all the member stocks, indicates solid near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperforms the bottom 50% by a factor of more than 2 to 1.
The industry’s positioning in the top 50% of the Zacks-ranked industries is a result of a positive earnings outlook for the constituent companies in aggregate. Looking at the aggregate earnings estimate revisions, it appears that analysts are gaining confidence in this group’s earnings growth potential. Since May 31, the industry’s 2020 earnings estimates have increased 22%.
Before we present a few stocks that you may want to consider for your portfolio, let’s take a look at the industry’s recent stock-market performance and valuation picture.
Industry Lags Sector and S&P 500
The Zacks Instruments – Scientific industry has underperformed the broader Zacks Computer and Technology sector as well as the S&P 500 composite over the past year.
The industry has gained 13.2% over this period compared with the S&P 500’s increase of 15.7% and against the broader sector’s rally of 37.7%.
Industry’s Current Valuation
On the basis of forward 12-month P/E, which is a commonly used multiple for valuing scientific instrument stocks, we see that the industry is currently trading at 23.71X compared with the S&P 500’s 22.84X and the Zacks Computer and Technology sector’s 26.74X.
Over the last five years, the industry has traded as high as 26.74X, as low as 18.41X and at the median of 22.64X, as the chart below shows.
4 Scientific Instruments Providers to Watch
Waltham, MA-headquartered PerkinElmer is strong on an expanding product portfolio, growing global exposure, and strengthening footprint in emerging markets like China and India. Moreover, solid demand for coronavirus testing tools is a tailwind.
Markedly, PerkinElemer’s ChemDraw software is leading the industry. The company is gaining market share backed by solid demand for Electronic Lab Notebooks that includes cloud-based Elements SaaS Offering and enterprise E-Notebook Solutions. Moreover, solid adoption of the TIBCO Spotfire platform for scientific data analytics is a key catalyst.
Acquisitions like that of Italy-based DANI Instruments and Cisbio Bioassays have expanded this Zacks Rank #1 (Strong Buy) company’s footprint in food, pharma and environmental and life sciences and diagnostics end-markets, respectively. You can see the complete list of today’s Zacks #1 Rank stocks here.
PerkinElemer shares have returned 17.7% year to date. The Zacks Consensus Estimate for its current-year earnings has been revised 39.9% north to $5.33 per share over the past 30 days.
Columbus, OH-domiciled Mettler-Toledo International has returned 19.6% year to date. This Zacks Rank #3 (Hold) company continues to see solid momentum across its Laboratory and Industrial segments. Markedly, Mettler-Toledo is the world’s largest manufacturer and marketer of weighing instruments for use in laboratory, industrial and food retailing applications.
Further, benefits from strategic investments in Spinnaker, marketing initiatives, field resources and product development are contributing well. Additionally, strengthening core industrial business is a major positive. Also, the company’s growing momentum in China remains a tailwind.
Pricing improvement and ongoing efficiency initiatives like SternDrive are expected to help in margin expansion over the long haul.
Moreover, the Zacks Consensus Estimate for the company’s current-year earnings has moved 10.5% north to $23.18 per share over the past 30 days.
Milford, MA-based, Waters Corporation is benefiting from growth in its top global pharma accounts. Solid momentum across new product lines like BioAccord and Cyclic IMS remains a positive. Further, the company’s growing investments in liquid chromatography (LC), LC-MS and chemistry categories are aiding it in gaining traction in the large molecule market. Also, growing momentum across biomedical research applications is another positive.
Markedly, Waters, which is currently one of the leading players in the mass spectrometry (MS) market, has been garnering significantly from the sale of its advanced MS instruments. Further, increasing regulation around food safety and quality, strict conditions for food testing, and environmental and fine chemical applications bode well for the company’s prospects. Additionally, strong execution of the company’s cost-cutting strategies remains a tailwind.
Additionally, the consensus mark for this Zacks Rank #3 company’s current-year earnings has moved 0.2% south to $8.03 per share over the past 30 days. Shares are down 11.8% year to date.
Another Zacks Rank #3 company, Bruker Corporation is well-poised to grow in the proteomics and spatial-omics fields. This Billerica, MA-headquartered company benefits from strong prospects in Nuclear Magnetic Resonance (NMR) industry, MALDI Biotyper and preclinical imaging (PCI) market.
Markedly, Bruker’s BioSpin products, which have specific application in structural proteomics, drug discovery, research and food and materials science fields, provide customers with the ability to ascertain the structure, dynamics, and function of specific molecules, such as proteins, as well as characterize and determine the composition of mixtures.
Moreover, demand for the MALDI Biotyper is increasing in applied markets, specifically for food, feed and beverage. Additionally, Bruker offers advanced PCI solutions for a broad spectrum of application fields, such as cancer research, functional and anatomical neuroimaging, orthopedics, cardiac imaging and stroke models. Moreover, this division is experiencing increasing customer demand for higher-strength pre-clinical magnetic resonance imaging system.
Notably, the Zacks Consensus Estimate for 2020 earnings has moved up 8.7% to $1.25 per share in the past 30 days. The stock has declined 22.1% on a year-to-date basis.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it’s predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce “the world’s first trillionaires,” but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks’ 3 Best Stocks to Play This Trend >>
Join us on Facbook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
Click to get this free report
PerkinElmer, Inc. (PKI): Free Stock Analysis Report
Waters Corporation (WAT): Free Stock Analysis Report
MettlerToledo International, Inc. (MTD): Free Stock Analysis Report
Bruker Corporation (BRKR): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.